CompanyGraph
Demant A/S
DEMANT · Nasdaq Copenhagen · Denmark
Price data from its 0RGT listing on LSE
demant.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $7.22B, above the global median of $1.18B
- PositionReturn on equity is 23.3%, higher than 95% of its Medical Devices peers (median 2.5%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
46.99BDKK7.22B · vs all stocks (USD)
Trailing P/E
26.14xvs Medical Devices peers
Revenue (TTM)
24.63BDKK3.78B · vs all stocks (USD)
Profit Margin
6.55%vs Medical Devices peers
Beta
0.7590xvs all stocks
52-Week Change
27.11%vs all stocks
Market Capitalization
46.99BDKK7.22B · vs all stocks (USD)
Enterprise Value
82.00BDKK12.60B · vs all stocks (USD)
Trailing P/E
26.14xvs Medical Devices peers
Forward P/E
18.86xvs Medical Devices peers
Price to Sales (TTM)
2.57xvs Medical Devices peers
Price to Book (MRQ)
5.64xvs Medical Devices peers
Enterprise to Revenue
3.33xvs Medical Devices peers
Enterprise to EBITDA
16.49xvs Medical Devices peers
Profit Margin
6.55%vs Medical Devices peers
Operating Margin
16.53%vs Medical Devices peers
Return on Assets (TTM)
7.29%vs Medical Devices peers
Return on Equity (TTM)
23.30%vs Medical Devices peers
Revenue (TTM)
24.63BDKK3.78B · vs all stocks (USD)
Revenue per Share (TTM)
116.71DKKUpdated Sep 20, 2026Quarterly Revenue Growth
14.80%vs Medical Devices peers
Gross Profit (TTM)
18.78BDKK2.89B · vs all stocks (USD)
EBITDA (TTM)
5.30BDKK814.50M · vs all stocks (USD)
Net Income (TTM)
2.42BDKK372.45M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.20%vs Medical Devices peers
Operating Cash Flow (TTM)
3.92BDKK602.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.76BDKK577.63M · vs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
77.00MDKKFY2025 · Dec 31, 2025Revenue
22.97BDKKFY2025 · Dec 31, 2025Cost of Goods Sold
5.60BDKKFY2025 · Dec 31, 2025Gross Profit
17.37BDKKFY2025 · Dec 31, 2025Operating Income
3.92BDKK602.92M · vs all stocks (USD)
Pre-tax Income
3.10BDKKFY2025 · Dec 31, 2025Income Tax Expense
734.00MDKKFY2025 · Dec 31, 2025Net Income
1.54BDKKFY2025 · Dec 31, 2025EBIT
3.65BDKKFY2025 · Dec 31, 2025EBITDA (Income Statement)
5.30BDKKFY2025 · Dec 31, 2025Research & Development
1.40BDKKFY2025 · Dec 31, 2025Selling, General & Administrative
12.05BDKKFY2025 · Dec 31, 2025Non-operating Interest Income
94.00MDKKFY2025 · Dec 31, 2025Non-operating Interest Expense
553.00MDKKFY2025 · Dec 31, 2025EPS (Basic)
7.31DKKFY2025 · Dec 31, 2025EPS (Diluted)
7.31DKKFY2025 · Dec 31, 2025Basic Shares Outstanding
211.31MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
211.31MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
3.83BDKKFY2025 · Dec 31, 2025Minority Interests (P&L)
1.00MDKKFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00DKKFY2025 · Dec 31, 2025Operating Cash Flow
3.67BDKKFY2025 · Dec 31, 2025Free Cash Flow
3.07BDKKFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.33BDKKFY2025 · Dec 31, 2025Starting Profit (CF Statement)
3.83BDKKFY2025 · Dec 31, 2025Other Non-cash Items
78.00MDKKFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-325.00MDKKFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
86.00MDKKFY2025 · Dec 31, 2025Capital Expenditures
-605.00MDKKFY2025 · Dec 31, 2025Net Intangibles (CF)
-205.00MDKKFY2025 · Dec 31, 2025Net Acquisitions
-6.29BDKKFY2025 · Dec 31, 2025Other Investing Activity
52.00MDKKFY2025 · Dec 31, 2025Net Investing Cash Flow
-6.84BDKKFY2025 · Dec 31, 2025Long-term Debt Issuance
8.32BDKKFY2025 · Dec 31, 2025Long-term Debt Payments
-3.47BDKKFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-167.00MDKKFY2025 · Dec 31, 2025Common Stock Repurchase
-582.00MDKKFY2025 · Dec 31, 2025Other Financing Charges
-2.00MDKKFY2025 · Dec 31, 2025Net Financing Cash Flow
4.10BDKKFY2025 · Dec 31, 2025Shares Outstanding
210.90MSharesUpdated Sep 20, 2026Float Shares
83.83MSharesUpdated Sep 20, 2026% Held by Insiders
60.00%vs all stocks
% Held by Institutions
18.74%vs all stocks
Total Cash (MRQ)
1.50BDKK229.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.09DKKUpdated Sep 20, 2026Total Debt (MRQ)
20.28BDKK3.12B · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.79xvs Medical Devices peers
Current Ratio (MRQ)
0.8210xvs Medical Devices peers
Book Value per Share (MRQ)
53.27DKKUpdated Sep 20, 2026Total Assets
39.07BDKK6.00B · vs all stocks (USD)
Total Current Assets
10.07BDKKFY2025 · Dec 31, 2025Total Liabilities
29.16BDKKFY2025 · Dec 31, 2025Total Non-current Assets
29.00BDKKFY2025 · Dec 31, 2025Total Non-current Liabilities
21.73BDKKFY2025 · Dec 31, 2025Total Current Liabilities
7.42BDKKFY2025 · Dec 31, 2025Cash
1.33BDKKFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.33BDKKFY2025 · Dec 31, 2025Accounts Receivable
3.77BDKKFY2025 · Dec 31, 2025Inventory
2.62BDKKFY2025 · Dec 31, 2025Accounts Payable
923.00MDKKFY2025 · Dec 31, 2025Short-term Debt
2.01BDKKFY2025 · Dec 31, 2025Other Current Liabilities
2.44BDKKFY2025 · Dec 31, 2025Long-term Debt
18.98BDKKFY2025 · Dec 31, 2025Other Non-current Liabilities
547.00MDKKFY2025 · Dec 31, 2025Common Stock (Book)
43.00MDKKFY2025 · Dec 31, 2025Total Shareholders' Equity
9.92BDKK1.52B · vs all stocks (USD)
52-Week Low
175.00DKKUpdated Sep 20, 202652-Week High
301.00DKKUpdated Sep 20, 202652-Week Change
27.11%vs all stocks
Beta
0.7590xvs all stocks
50-Day MA
285.81DKKUpdated Sep 20, 2026200-Day MA
235.01DKKUpdated Sep 20, 2026Avg 10-Day Volume
209.39KSharesUpdated Sep 20, 2026Avg 30-Day Volume
285.76KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
11.49DKKUpdated Sep 20, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 23.3%, higher than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: 0.23Industry median: 0.03Industry P95: 0.17Peers compared: 102
Current ratio is 0.82×, lower than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 0.82Industry median: 3.87Industry P5: 1.33Peers compared: 102
Debt-to-equity is 1.79×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 1.79Industry median: 0.11Industry P95: 1.28Peers compared: 102
Financial Health
Altman Z-Score 1.94: grey zoneSignificant
Altman Z-Score: 1.94
High earnings qualityNotable
Earnings Quality Score: 1.10
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $7.22B, above the global median of $1.18BNotable
Market cap (USD): 7,220,161,142.439Global Median: 1,180,223,658.953
Revenue is $3.78B, above the global median of $548.88MNotable
Revenue (USD): 3,784,553,002.496Global Median: 548,883,780.48
Levered free cash flow is $577.63M, above the global median of $18.73MNotable
Levered free cash flow (USD): 577,627,984.73Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Allist Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunovant Inc.
Tier 1ProductionApproval-Gated PipelineRule
Alkermes plc
Tier 1ProductionApproval-Gated PipelineRule
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Rhythm Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
4 interpretationsFCF Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin
Dollarama Inc.
5 interpretationsFCF Ratios ElevatedElevated ROE With High Debt-to-Equity and Equity MultiplierMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
4 interpretationsFCF Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedMulti-Year FCF With Growth And Margin